Document is current
Any future updates will be listed below
-
Authors
Anabtawi, Nadeen https://orcid.org/0000-0002-1317-8460
Nicolet, Deedra
Alotaibi, Najla
Buelow, Daelynn R.
Orwick, Shelley https://orcid.org/0000-0002-4537-1409
Gregory, Thomas https://orcid.org/0000-0001-9357-369X
Raj, Ruchika
Coleman, Kennedy https://orcid.org/0009-0001-9940-0236
Kolitz, Jonathan E.
Powell, Bayard L.
Blum, William G.
Baer, Maria R.
Byrd, John C. https://orcid.org/0000-0002-8778-1000
Stock, Wendy https://orcid.org/0000-0002-8349-9200
Uy, Geoffrey L. https://orcid.org/0000-0002-7809-0996
Mrózek, Krzysztof https://orcid.org/0000-0002-1408-5063
Eisfeld, Ann-Kathrin https://orcid.org/0000-0001-6442-1419
Cheng, Xiaolin
Baker, Sharyn D. https://orcid.org/0000-0003-3062-3252
Blachly, James S. https://orcid.org/0000-0002-4275-5562
- License Information
-
More Information
Article History
Received: 20 November 2024
Revised: 22 November 2024
Accepted: 4 December 2024
First Online: 13 January 2025
Competing interests
: JSB is a consultant for and reported honoraria from KITE, INNATE, Syndax, AstraZeneca and AbbVie. BLP is a consultant for Cornerstone Pharmaceuticals and reported research funding from Ambit Biosciences, Cornerstone, Genentech, Hoffman LaRoche, Jazz Pharmaceuticals, Novartis and Pfizer. WGB reported honoraria from Abbvie, Syndax, and AmerisourceBergen and research funding from Celyad Oncology, Nkarta, Xencor, Forma Therapeutics and Leukemia and Lymphoma Society. GLU is a consultant for AbbVie, Agios, Jazz, GlaxoSmithKline, Genentech, and Novartis; reported honoraria from Astellas and research funding from Macrogenics. JCB consults for Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; receives honoraria from Astellas, AstraZeneca, Novartis, Pharmacyclics, Syndax and Trillium; he is a Chairman of the Scientific Advisory Board of Vincerx Pharmaceuticals and a member of advisory committee of Newave; and is a current equity holder of Vincerx Pharmaceuticals. A-KE is the spouse of Christopher J. Walker who is currently employed by Karyopharm Therapeutics. The remaining authors declare no competing financial interests.
: All methods in this study were performed in accordance with the U.S. regulatory guidelines and respected the principles outlined in the Declaration of Helsinki. Specifically, the trials complied with the U.S. Food and Drug Administration regulations outlined in 21 CFR Parts 50 and 56, which govern the protection of human subjects and the functioning of Institutional Review Boards (IRBs). Additionally, the trials adhered to the principles of the Common Rule and the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use Good Clinical Practice Guidelines. All patients included in this study provided written informed consent for participation in treatment studies and for the research use of their specimens. Study protocols were reviewed and approved by the IRB at each participating institution (for information about participating institutions see the Supplementary information).
